$IDYA
IDEAYA Biosciences, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$37.36
▼-1.19%-$0.450
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateIDEAYA Biosciences, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is IDYA down today? It is at $37.36 (-1.19%), and our scanner flagged it 51 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment IDYA spikes, and full due diligence on IDYA — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $IDYA 51 times in the last 30 days. Create a free account to track $IDYA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on IDYA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for IDYA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Ruiz Briseno Andres Officer | Sold (automatic/other) | -10K | sold 27% | 26K | $382K at $40.01 | Jul 7, 26 |
Ruiz Briseno Andres Officer | Other | 10K | added 36% | 36K | $123K at $12.86 | Jul 7, 26 |
Stein Jeffrey Director | Bought (open market) | +50K 0.05% of company | added 100% | 54K | $1.6M at $32.96 | Mar 2, 26 |
Ruiz Briseno Andres Officer | Acquired (grant/award) | +1K | added 5.0% | 26K | $21K at $16.91 | Nov 28, 25 |
Snyder Douglas B. Officer | Acquired (grant/award) | +1K | added 100% | 2K | $18K at $16.91 | Nov 28, 25 |
Snyder Douglas B. Officer | Acquired (grant/award) | +1K | n/a | 1K | $18K at $16.91 | May 30, 25 |
Hata Yujiro S Officer | Other | 13K 0.01% of company | added 1.9% | 691K | $250K at $19.52 | Feb 18, 25 |
Ruiz Briseno Andres Officer | Acquired (grant/award) | +682 | added 2.8% | 25K | $16K at $23.26 | Nov 29, 24 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on IDYA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for IDYA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
IDYA last traded at $37.36, down 1.19% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
IDEAYA Biosciences, Inc. Common Stock (IDYA) is next expected to report earnings on Tuesday, November 3, 2026, about 30 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The IDYA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged IDYA 51 times in the last 30 days.
IDYA (IDEAYA Biosciences, Inc. Common Stock) trades on XNAS, with a market cap of about $3.60B in the PHARMACEUTICAL PREPARATIONS sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge IDYA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$IDYA discussion
Sign in to ask a question or join the discussion.